HARROW, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Harrow entered into a definitive agreement to acquire global rights to TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris Inc. for $30 million upfront cash payment plus up to $70 million in contingent milestone payments tied to net sales (total potential consideration $100 million). TYRVAYA is FDA-approved for dry eye disease signs and symptoms, currently marketed in U.S., China, and Taiwan, and complements Harrow's flagship VEVYE product with a different mechanism of action (stimulates basal tear production via nasal spray versus VEVYE's inflammatory approach via eye drops). Transaction expected to close in H2 2026 and is projected to be accretive shortly after closing.
Why this rating
Meaningful M&A for ~$1B company; $30M upfront is ~3% of market cap. Strategically expands dry eye franchise with complementary product already generating revenue, leveraging existing infrastructure.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.